{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-164835","form_type":"8-K","ticker":"KURA","cik":"0001422143","company_name":"Kura Oncology, Inc.","filed_at":"2023-06-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.799886+00:00","generated_at":"2026-06-14T02:51:32.021898+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Kura Oncology reports 35% CR rate with ziftomenib in NPM1-mutant AML at EHA 2023","bullets":["7 of 20 NPM1-mutant AML patients at 600 mg RP2D achieved complete remission (CR) with full count recovery.","Median duration of response 8.2 months; median follow-up 8.8 months; 2 patients underwent SCT and remain in remission.","MEN1-M3271 resistance mutation detected in only 1 of 29 patients post-ziftomenib; ziftomenib active against MEN1-T349M.","Phase 2 registration-directed study (85 patients, 62 sites) enrollment outperforming projections; combination studies initiating.","Differentiation syndrome manageable: 15% Grade 1/2, 5% Grade 3; safety profile consistent with underlying disease."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-164835","json":"https://secwatch.observer/filing/0001193125-23-164835.json","markdown":"https://secwatch.observer/filing/0001193125-23-164835.md","text":"https://secwatch.observer/filing/0001193125-23-164835.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1422143/000119312523164835/0001193125-23-164835-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1422143/000119312523164835/d450277d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T02:51:32.021898+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}